4 Questions After Amgen-Sandoz Rehearing Bids Fizzle Out
The Federal Circuit's refusal to rehear an epic fight between Amgen Inc. and Sandoz Inc. over the Affordable Care Act's biosimilars pathway raises the prospect of U.S. Supreme Court review and...To view the full article, register now.
Already a subscriber? Click here to view full article